Clinical Trial Update: Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD) [Phase 2]

View source ↗

Summary

The Phase 2 extension of carbidopa-levodopa for neovascular age-related macular degeneration has completed enrollment. Results were posted on 2025-09-12.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• carbidopa-levodopa (carbidopa-levodopa)

Snippet

Sponsor: Snyder, Robert W., M.D., Ph.D., P.C. | Conditions: Macula; Degeneration, Retina | Phase 2 | Status: COMPLETED | Results posted: 2025-09-12